Michael Gelband’s Pacira BioSciences PCRX Stock Holding History

Michael Gelband’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.55M	Buy	+60,963	New	+$1.44M	0.01%	928
2025 Q4	–	Sell	-58,290	Closed	-$1.5M	–	1944
2025 Q3	$1.5M	Buy	+58,290	New	+$1.43M	0.02%	826
2025 Q2	–	Sell	-283,982	Closed	-$7.06M	–	1858
2025 Q1	$7.06M	Buy	283,982 +71,158	+33%	+$1.7M	0.07%	308
2024 Q4	$4.01M	Buy	212,824 +148,842	+233%	+$2.61M	0.03%	501
2024 Q3	$963K	Buy	+63,982	New	+$1.09M	0.01%	980
2024 Q2	–	Sell	-26,643	Closed	-$779K	–	1871
2024 Q1	$779K	Buy	+26,643	New	+$818K	0.01%	1025
2023 Q4	–	Sell	-14,707	Closed	-$451K	–	1911
2023 Q3	$451K	Sell	14,707 -8,908	-38%	-$321K	﹤0.01%	1279
2023 Q2	$946K	Buy	23,615 +98	+0.4%	+$4.05K	0.01%	1121
2023 Q1	$960K	Sell	23,517 -32,097	-58%	-$1.28M	0.01%	1147
2022 Q4	$2.15M	Buy	+55,614	New	+$2.71M	0.03%	605
2022 Q3	–	Sell	-17,069	Closed	-$995K	–	2198
2022 Q2	$995K	Buy	+17,069	New	+$1.12M	0.01%	1080
2020 Q4	–	Sell	-12,173	Closed	-$732K	–	2285
2020 Q3	$732K	Buy	+12,173	New	+$707K	0.01%	820
2020 Q1	–	Sell	-24,567	Closed	-$1.11M	–	1503
2019 Q4	$1.11M	Buy	24,567 +1,094	+5%	+$46.5K	0.02%	512
2019 Q3	$894K	Sell	23,473 -24,485	-51%	-$977K	0.03%	423
2019 Q2	$2.09M	Buy	+47,958	New	+$2.04M	0.08%	150
2019 Q1	–	Sell	-7,786	Closed	-$335K	–	741
2018 Q4	$335K	Buy	+7,786	New	+$363K	0.02%	185

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Michael Gelband's PCRX Position: Q2 2026 in Review

Michael Gelband opened a new position in Pacira BioSciences (PCRX) in Q2 2026: 60,963 shares worth $1.55M. The stake represents 0.01% of the portfolio and ranks #928 among its holdings. This is a return to the name: Michael Gelband previously reported a position in PCRX as recently as Q3 2025.

Michael Gelband first reported a position in PCRX in Q4 2018 and has held it in 16 quarters since. The position peaked at $7.06M in Q1 2025. 251 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Michael Gelband held 60,963 shares of Pacira BioSciences worth $1.55M as of Q2 2026.
Pacira BioSciences was a new Michael Gelband position in Q2 2026.
Pacira BioSciences made up 0.01% of Michael Gelband's portfolio in Q2 2026, its #928 holding.
Michael Gelband first reported a position in Pacira BioSciences in Q4 2018 and has held it in 16 quarters since.
Michael Gelband's Pacira BioSciences position peaked at $7.06M in Q1 2025.
251 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.